GlobalRPh Renal Dosing Masterv6.6
Source review / handoff

Ceftolozane / tazobactam (Zerbaxa)

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Return to full drug recordAll source differencesRead selected sourcesHow to use this review

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Record caution: Label-version change: the May 2026 DailyMed pediatric renal table is now local. Older pediatric evidence-gap statements remain historical; read the new age-specific source before selecting a regimen.

U.S. labeling, UCSF and Nebraska distinguish indication and infusion duration. Nebraska uses a 4-hour inpatient infusion; the label uses 1 hour. Keep each renal table with its indication and infusion method.

Check source scope before reading a dose

Nebraska Medicine - ZERBAXA inpatient extended infusion

Product / population
Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.
Renal method
CrCl in mL/min where specified; no equation inferred.
Source revision
Retrieved PDF page 15; revision date not independently established
Retrieved
2026-09-05
Local review status
Locally included source-specific summary. Regimen differences are not automatically resolved.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

One-hour labeling versus institutional extended infusion

The RX label table uses a one-hour infusion. The UCSF protocol uses a three-hour infusion. Both also separate urinary/intra-abdominal infection from pneumonia/severe infection.

What to reconcile: Keep the selected source dose, indication, renal band, loading instruction and infusion duration together.

Source difference identified; final patient-specific adjudication required.

Open this note and its source references

Pediatric renal guidance changed after the RX mirror

The older mirror lacks the age-specific renal regimens now supplied by the May 2026 label.

What to reconcile: Use the new pediatric card for ages two and older; verify indication, pediatric eGFR, weight caps and infusion time. Do not use adult Cockcroft-Gault bands as pediatric instructions.

Source-specific interpretation; independent clinician adjudication pending.

Open this note and its source references
Professional

Nebraska Medicine - ZERBAXA inpatient extended infusion

Open original reference

Nebraska Medicine / UNMC · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: CrCl in mL/min where specified; no equation inferred.
Source date: Retrieved PDF page 15; revision date not independently established
Retrieved: 2026-09-05

Source recheck unresolved. Prior follow-up retrieval/version warning retained; not resolved by v6.0. Read source-review status

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Adults: cUTI/cIAI baseline 1.5 g IV every 8 hours; CrCl 30-50, 750 mg every 8 hours; 15-29, 375 mg every 8 hours; HD, 750 mg load then 150 mg every 8 hours.

HAP/VAP or septic shock: baseline 3 g every 8 hours; 30-50, 1.5 g every 8 hours; 15-29, 750 mg every 8 hours; HD, 2.25 g load then 450 mg every 8 hours. Inpatient infusions run over 4 hours, unlike the label's 1 hour. Only the adult rows are summarized.

RDM30-108-ceftolozane-tazobactam-1 · Source locator: Nebraska Medicine - ZERBAXA inpatient extended infusion; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://www.unmc.edu/intmed/_documents/id/asp/dose-nm-anti-infective-renal-dosing-guidelines.pdf
Retrieved
2026-09-05
Renal-function method
CrCl in mL/min where specified; no equation inferred.
Source date/version
Retrieved PDF page 15; revision date not independently established
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
d963026ae5b3236cd15d309c462f55fe40cab54b36b14ef5ccfdf87dfbca7262

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=ceftolozane-tazobactam&s1=RDM30-108-ceftolozane-tazobactam&h1=ddbf941fa4459f12032469e47373530769afd61282d972f27b70abacd44be393